TuttoCongressi
E-mail
Password
 Resta Collegato

Cerca per parole nell'archivio:
In archivio:
  • N° Relazioni: 478
  • N° Accessi Relaz.: 168922
Web Video
Portale Giovani Medici

   home   |   progetto   |   chi siamo   |   servizi   |   contatti   |   note legali Live Demo

   Mostra tutti | Mostra contenuti EasyRec   
10/04/2010
AUDITORIUM
15.00 - 15.15
SCIENTIFIC SESSIONS - CONFERENCE WELCOME/ORIENTATION - TRAVEL FELLOWS ARE REQUIRED TO ATTEND
Intro 
15.15 - 17.00
ETHICS SYMPOSIA
Sartorius Norman 
Ethic Symposia
Stephen Marder 
Conflict of Interest in Medical Research
17.00 - 18.30
KEYNOTE LECTURE
Elyn Saks 
The Center Cannot Hold: My Journey through Madness
 
11/04/2010
AUDITORIUM
08.30 - 10.30
PLENARY SESSION - ANTICIPATING DSM-V: NEW PARADIGMS
William Carpenter 
DSM-V: New Paradigms and other Controversies
Richard Keefe 
Neurocognition
Alex Hofer 
Social Cognition
Dieter Naber 
Quality of Life
Kim Mueser 
Return to Work
10.30 - 12.00
NEW DIRECTIONS FOR ANIMAL MODELING IN SCHIZOPHRENIA
Bita Moghaddam 
New Directions for Animal Modeling in Schizophrenia
Inna Gaisler-Salomon 
Interfacing NMDA deficiency and other pharmacological model with genetic models.
Akira Sawa 
Moving from gene to function in mutant model of schizophrenia
Patricio O'Donnell 
Developmental animal models, thinking beyond the lesion models
Peter J. Uhlhaas 
Translational measures of function in animal models of schizophrenia
Bita Moghaddam 
conclusion
13.30 - 15.30
GENE EXPRESSION IN SCHIZOPHRENIA - ANIMAL MODELS AND POSTMORTEM STUDIES
Karoly Mirnics 
Novel animal models for studying schizophrenia: BAC-driven miRNA-mediated in vivo silencing of gene expression
Schahram Akbarian 
Epigenome mapping in developing and diseased prefrontal cortex
Amanda Law 
ErbB4 and PI3KCD and are Interacting Biological and Genetic Factors That Regulate NRG1-mediated PI3K Signaling and Risk for Schizophrenia.
David Porteous 
DISC1 Pathway Expression in Mouse and Man
15.30 - 17.30
MULTIPLE MECHANISMS FOR THE GENETIC BASIS FOR SCHIZOPHRENIA
Pablo Gejman 
Multiple common Gene variants in SZ: The GWAS Data
Sibylle Schwab, Dieter Wildenauer 
Candidate genes from linked chromosomal regions: What happened to Neuregulin and Dysbindin?
James Kennedy 
 
Palaffari-1-F
15.30 - 17.30
AN UPDATE ON THE NEXT WAVE OF SCHIZOPHRENIA THERAPEUTICS
Discussant - Anthony Grace 
 
Palaffari-2-F
15.30 - 17.30
MAKING CONNECTIONS: ABNORMAL WHITE MATTER DEVELOPMENT IN THE EARLY STAGES OF SCHIZOPHRENIA
Discussant - Sophia Frangou 
 
Palaffari-3-F
15.30 - 17.30
EARLY INTERVENTION SERVICES FOR FIVE YEARS?
Discussant - Max Birchwood 
 
12/04/2010
AUDITORIUM
08.30 - 09.30
PLENARY SESSION - CLINICAL IMPLICATIONS OF RECENT GENETIC FINDINGS: GWAS, ENDOPHENOTYPES AND COMMERCIAL TESTING
Michael Owen 
09.30 - 10.30
WHERE HAVE THE NEW GWAS GOTTEN US?
Peter Visscher 
Pablo Gejman 
10.30 - 11.00
IS THE ENDOPHENOTYPE CONCEPT USEFUL IN DEFINING GENES FOR SCHIZOPHRENIA?
Lynn DeLisi 
Dan Rujescu 
11.00 - 12.00
WILL COMMERCIAL DNA TESTING EVER BE AS USEFUL TOOL IN THE CLINIC FOR SCHIZOPHRENIA?
James Kennedy 
13.30 - 15.30
IMPROVING NEUROCOGNITION IN SCHIZOPHRENIA: REPORTS FROM NIMH TURNS AND MATRICS-CT
Donald C. Goff 
Searching for Cognitive Enhancers in Schizophrenia: The TURNS Program Strategy
Daniel C. Javitt 
Effects of intranasal AL-108 (Davunetide) on neurocognition and functional outcome in schizopherenia
Robert W. Buchanan 
MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia
Michael F. Green 
Validation of Intermediate (Co-primary) Measures for Clinical Trials of Cognition-enhancing Drugs for Schizophrenia
Discussant - Wolfgang Fleischhacker 
15.30 - 17.30
PHARMACOGENOMICS IN SCHIZOPHRENIA: HOW FAR TO THE CLINIC?
James Kennedy 
Issues regarding genetic testing for schizophrenia risk and for antipsychotic drug effects.
Alessandro Serretti 
Methods for obtaining clinically useful pharmacogenetic predictors; An example of a detailed investigation in an haloperidol treated sample
Alessandro Bertolino 
Use of intermediate phenotypes in pharmacogenetics
Anil Malhotra 
Pharmacogenomic approaches to rare and common side effects associated with antipsychotic drug treatment
Discussant - James Kennedy 
 
Palaffari-1-F
13.30 - 15.30
THE MANY FACES OF PSYCHOSIS
Discussant - Carol Tamminga 
15.30 - 17.30
EINHEITSPSYCHOSE? COMPARISON OF SCHIZOPHRENIA AND BIPOLAR DISORDER ACROSS GENES, BRAIN, AND BEHAVIOUR
Discussant - Robin Murray 
 
Palaffari-2-F
13.30 - 15.30
GENE-BRAIN INTERACTION IN THE PATHOPHYSIOLOGY OF PSYCHOSIS
Discussant - Joseph Callicott 
15.30 - 17.30
MUTANT MODELS AND PSYCHOSIS AT THE CROSSROADS: A CRITICAL RE-EVALUATION OF TECHNIQUES AND TRANSLATION
Discussant - Paul Harrison 
 
Palaffari-3-F
13.30 - 15.30
NEW DEVELOPMENTS IN FAMILY PSYCHOEDUCATION
Discussant - Lisa Dixon 
15.30 - 17.30
NEW RESEARCH IN THE EARLY PREDICTION OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA
Discussant - John Kane 
 
Palaffari-G-F
13.30 - 15.30
NEURAL SUBSTRATES OF THE ASSOCIATION BETWEEN CANNABIS AND SCHIZOPHRENIA
Discussant - Zerrin Atakan 
15.30 - 17.30
VOCATIONAL RECOVERY IN FIRST EPISODE PSYCHOSIS: INTERNATIONAL EVIDENCE FOR EARLY INTERVENTION
Discussant - Kim T. Mueser 
 
13/04/2010
AUDITORIUM
08.30 - 12.00
PLENARY SESSION: ON THE MATTER OF NEUROIMAGING IN THE CONTEXT OF SCHIZOPHRENIA GENETICS
Daniel Weinberger 
Alessandro Bertolino 
.
Philip McGuire 
Eva Meisenzahl 
Andreas Meyer-Lindenberg 
Steven Potkin 
Si Tianmei 
13.30 - 15.30
ORAL PRESENTATIONS - PATHWAYS TO PSYCHOSIS & MISC NEUROCHEMISTRY
A. George Awad 
Subjective Tolerability to Antipsychotics in Schizophrenia, Over 30 Years of Research: Are We on the Verge of a New Science of "Subjective Tolerability Disorders"
Gabriela Novak 
Hyperactive mice show elevated D2High receptors, a model for schizophrenia: calcium/calmodulin-dependent kinase II alpha knockouts
Philipp A. Csomor 
Impact of neurochemical manipulation on sensory gating in healthy subjects with low gating levels - a validation study
Deepak Cyril D'Souza 
Glycine Transporter Inhibition Attenuates the Psychotomimetic Effects of Ketamine in Healthy Human Subjects
Douglas L. Noordsy 
Are There Synergistic Interactions Between Antipsychotic Medications and Psychosocial Rehabilitation? Evidence From A Double-Blind Randomized Trial of Risperidone vs. Olanzapine Among Participants In Vocational Rehabilitation
Ruchika Gajwani 
Developmental pathways to emotional dysfunction in young people at ultra-high risk of developing psychosis
Andrew Thompson 
Predictive validity of clinical variables in the "at risk" for psychosis population: international comparison with results from the North American Prodromal Longitudinal Study
Ulrich Reininghaus 
A sociodevelopmental pathway to psychosis? New evidence from the ÆSOP study
15.30 - 17.30
DYSREGULATION OF THE DOPAMINE SYSTEM: THE FINAL COMMON PATHWAY TO SCHIZOPHRENIA?
Anthony Grace 
The neurodevelopmental perspective: Dopamine system overdrive by the hippocampus in an animal model of schizophrenia and reversal by antipsychotic drugs
Alain Dagher 
The Role of Environmental Factors
Oliver Howes 
Dopamine dysregulation: pathophysiology or endophenotype?
Anissa Abi-Dargham 
Linking dopamine dysregulation to symptoms and clinical phase brain imaging studies
Discussant - Shitij Kapur 
 
Palaffari-1-F
15.30 - 17.30
IMPROVING SIGNAL DETECTION IN SCHIZOPHRENIA CLINICAL TRIALS BY MULTIPLE METHODS
Discussant - Wolfgang Fleischhacker 
 
Palaffari-2-F
15.30 - 17.30
BRAIN PROGRESSION IN SCHIZOPHRENIA: WHO, WHERE, WHEN, WHY
Discussant - Lynn DeLisi 
 
Palaffari-3-F
15.30 - 17.30
FUTURE DIRECTIONS FOR THE NEUROPATHOLOGY OF SCHIZOPHRENIA
Discussant - joel Kleinman 
 
Palaffari-G-F
15.30 - 17.30
AUTISTIC AND COGNITIVE TRAITS IN THE GENETIC UNDERSTANDING OF THE CONTINUUM IN NEURODEVELOPMENTAL DISORDERS AND FUNCTIONAL PSYCHOSIS
Discussant - Celso Arango 
 
14/04/2010
AUDITORIUM
08.30 - 10.30
BRAIN MATURATION DURING ADOLESCENCE AND THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA: RELEVANCE FOR UNDERSTANDING PSYCHOSIS, COGNITIVE DYSFUNCTIONS AND IMPLICATIONS FOR TREATMENT
David A. Lewis 
Developmental refinements in synaptic markers of cortical GABA transmission
Cynthia Shannon Weickert 
Protracted development of cortical inhibition and its relationship to schizophrenia.
Nitin Gogtay 
Advances in neuroimaging allow prospective study of human brain development
Peter J. Uhlhaas 
Development of Task-Related Neural Synchrony and the Pathophysiology of Schizophrenia
Discussant - Christos Pantelis 
10.30 - 12.30
GENETIC, EPIGENETIC, AND MOLECULAR ASPECTS OF GABA FUNCTION IN THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA
Daniel R. Weinberger 
Genetic regulation of GABA activity and risk for schizophrenia
Schahram Akbarian 
Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia
Karoly Mirnics 
GABA-ergic dysfunction in schizophrenia: from postmortem studies to animal models
Alessandro Guidotti 
GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon
Discussant - Dennis Grayson 
14.00 - 16.00
GENE-ENVIRONMENT INTERACTIONS IN SCHIZOPHRENIA: ADVANCING BASIC AND CLINICAL RESEARCH
Jim van Os 
Momentary Assessment Technology to Assess Gene-Environment Interactions Underlying the Affective Intermediary Phenotype of Stress Sensitivity in Schizophrenia
Andreas Meyer-Lindenberg 
Mechanisms of GEI in schizophrenia
Jonathon Arnold 
An Animal Model of a Gene-Environment Interaction: The Role of NRG1 in Cannabis-Induced Schizophrenia
Mikhail Pletnikov 
Gene-environment interactions in schizophrenia: a new mouse model
Discussant - Mary Cannon 
 
Palaffari-1-F
08.30 - 10.30
MOVEMENT DISORDERS SHOULD BE A CRITERION FOR SCHIZOPHRENIA IN DSM-V
Discussant - Inez Myin-Germeys 
10.30 - 12.30
IMPROVING OVERALL OUTCOMES - EXTENDING CBTP TO COMPLEX PROBLEMS
Discussant - Til Wykes 
14.00 - 16.00
INTEGRATION OF STRUCTURAL, FUNCTIONAL AND NEUROCHEMICAL BRAIN CHANGES PRIOR TO THE ONSET OF PSYCHOSIS
Discussant - Shitij Kapur 
 
Palaffari-2-F
08.30 - 10.30
PSYCHOTIC SYMPTOMS IN THE COMMUNITY: WHERE ARE WE TODAY?
Discussant - Shitij Kapur 
10.30 - 12.30
DYNAMIC BRAIN CHANGES IN SCHIZOPHRENIA ACROSS THE LIFESPAN: INFLUENCE OF GENETIC AND ENVIRONMENTAL FACTORS.
Discussant - David Lewis 
14.00 - 16.00
NEWER ANTIPSYCHOTIC DRUGS IN EARLY-ONSET PSYCHOSIS: A TRANSLATIONAL VIEW
Discussant - Nina Schooler 
 
Palaffari-3-F
08.30 - 10.30
UPDATE ON DURATION OF UNTREATED PSYCHOSIS; ITS IMPACT ON OUTCOME, AND FINDING WAYS TO ITS REDUCTION
Discussant - Max Marshall 
10.30 - 12.30
RISK FACTORS IN THE DEVELOPMENT OF PSYCHOSIS: COMMON PATHOPHYSIOLOGICAL VARIABLES PROVIDE AN INSIGHT INTO THE ETIOLOGY AND TREATMENT OF SCHIZOPHRENIA
Discussant - Elaine Walker 
14.00 - 16.00
CANNABIS, AMPHETAMINES AND EARLY PSYCHOSIS: EVALUATING THE RISKS FOR PROGRESSION, NEUROBIOLOGIC MODELS OF INTERACTION AND IMPLICATIONS FOR TREATMENT
Discussant - John Kane 
 
Palaffari-G-F
08.30 - 10.30
INTERNATIONAL PERSPECTIVES ON GROUP BASED APPROACHES TO TREATING COGNITION IN SCHIZOPHRENIA
Discusant - Til Wykes 
10.30 - 12.30
PERFORMANCE-BASED ASSESSMENT OF DISABILITY: VALIDITY ACROSS DIFFERENT CULTURES AND AGE-RANGES
Discussant - Richiard S. Keefe 
14.00 - 16.00
SCHIZOPHRENIA AND HOMELESSNESS
Discussant - Carol L. M. Caton 
 

   home   |   progetto   |   chi siamo   |   servizi   |   contatti   |   note legali
Tuttocongressi ©1995 - 2026 | Via Dei Perfetti Ricasoli, 94-96 - 50127 Firenze  |  P.Iva 03755090481